

**REMARKS**

The communication from the Examiner dated March 14, 2002 separated the present application into 94 inventions. These groupings included:

Inventions 1-23: recited in claims 46-58, drawn to a complex comprising a peptide derived from glutamic acid decarboxylase;

Inventions 24-46: recited in claims 59-61, drawn to a method of treating or preventing an autoimmune disease or diabetes, or causing an immune response or immune tolerance in a patient by administering a substance according to Inventions 1-23;

Inventions 47-70: recited in claims 62-76, drawn to an oligomerized peptide, peptide derivative/MHC molecule or MHC molecule derivative complex; and

Inventions 71-94: recited in claims 77-79, drawn to a method of treating or preventing an autoimmune disease or diabetes or causing an immune response or immune tolerance in a patient by administering the substance of Inventions 47-70.

Applicants were required not only to choose one of the four categories of inventions, but also to choose one SEQ ID NO. for examination. Applicants elected for prosecution Inventions I-XXIII, and Sequence Number 2 in the Response to the Restriction Requirement dated November 13, 2001.

The communication from the Examiner dated March 14, 2002 rejected Applicants' Response to the Restriction Requirement and declared that the Response was not fully responsive because a single group had not been selected.

Applicants' representative contacted the Examiner for clarification of the rejection. Applicants thank the Examiner for the courtesies shown to their representative during these conversations. It is the understanding of the Applicants

that the communication is a request to reword the election. Applicants herein state that the invention labeled "Group I," which is defined as Claims 46-58 directed towards SEQ ID NO. 2, is elected for prosecution. Applicants, of course, maintain the previous traversal of the Restriction Requirement and reiterate herein all positions stated in the the Response to the Restriction Requirement dated November 13, 2001.

Additionally, it was noted that the present application does not comply with the requirements of 37 CFR 1.821-1.825. These rules are directed towards sequence listing requirements. In particular, the application has been objected to due to the fact that the tags disclosed in Figures I and II are not labeled with SEQ ID NOS. Applicants attach to this response proposed amended Figures which contain the appropriate SEQ ID NOS (SEQ ID NO: 19-22 for Figure 1 and SEQ ID NO: 23-39 for Figure 2), in red, and have amended the description of these Figures (see pages 25-26 of the specification) to recite the same.

In the event any fees are required with this paper, please charge Deposit Account No. 01-2300, referring to client-matter number 100564-09035.

Respectfully submitted,  
ARENT FOX KINTNER PLOTKIN & KAHN PLLC



D. Daniel Dzara, II  
Attorney for Applicants  
Registration No. 47,543

Customer No.: 004372  
1050 Connecticut Avenue, NW, Suite 400  
Washington, DC 20036-5339  
Telephone: (202) 857-6000

DDD:

Enclosures: Proposed Corrected Drawings  
Marked Up Copy of Specification  
Submission of Proposed Corrected Drawings  
Petition for Extension of Time for One Month

**MARKED UP COPY OF SPECIFICATION**

Page 25, lines 31-32:

Fig.1 shows autoreactive amino acid sequences (SEQ ID NO:19-22) according to the invention.

Page 25, line 34, and page 26, line 1:

Fig. 2 shows further autoreactive amino acid sequences (SEQ ID NO:23-39) according to the invention.